Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

Formulations for parenteral administration may include but are not limited to sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on the severity of the symptoms of arrhythmic or fibrillating occurrence and on the responsiveness of the subject to the tricyclic dibenzoazepin derivatives. Persons of ordinary skill in the art can easily determine optimum dosages, dosing methodologies and repetition rates.

Example 6

Method of treatment or prevention of ventricular fibrillation

As noted above, the compounds of the present invention, which are tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, have been shown to be effective defibrillating agents. The following example is an illustration only of a method of treating VF with the dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, and is not intended to be limiting.

The method includes the step of administering the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivatives, in a pharmaceutically acceptable carrier as described in Example 5 above, to a subject to be treated. The tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the prevention of VF occurrence or abnormal cardiac activity. Optionally and preferably, the compound is administered parenterally.

According to another preferred embodiment of the present invention, the compound is used as an adjunct or additive treatment for a patient who has received an implanted defibrillator, such that the compound is administered to the patient as previously described.

Example 7

Method of manufacture of a medicament containing a tricyclic dibenzazepin and 11-Oxo-dibenzodiazepin derivative

The following is an example of a method of manufacturing a tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivative. First, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is synthesized in accordance with good pharmaceutical manufacturing practice. Examples of methods of synthesizing the tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives were given previously herein. Next, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is placed in a suitable pharmaceutical carrier, as described in Example 5 above, again in accordance with good pharmaceutical manufacturing practice.

It will be appreciated that the above descriptions are intended only to serve as examples, and that many other embodiments are possible within the spirit and the scope of the present invention.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

LIST OF REFERENCES CITED

1. Olshausen K.V., Witt T., Pop T., Treese N., Bethge K., Meyer J. Sudden cardiac death while wearing a Holter monitor. Am. J. Cardiol., 67: 381-386, 1991.
2. Vaughan Williams E.M. Classification of antiarrhythmic drugs. In: Sandoe E., Flasted-Jansen E. Olesen K.H., eds. Symposium on Cardiac Arrythmias. Sudertalje Seden: AB Astra, pp. 449-472, 1970.
3. Sanna G., Archidiacono R. Chemical ventricular defibrillation of the human heart with bretylium tosylate. Am. J. Cardiol. 32: 982-986, 1973.
4. CAST Investigators. Preliminary report: Effect of ecainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321: 406-412, 1989.
5. CAST II Investigators - Effect of the antiarrhythmic agent moricizine on after myocardial infarction. N. Engl. J. Med. 327: 227-233, 1992.
6. Manoach M., Varon D., Neuman M., Erez M. Editorial – A new group of defibrillatory drugs in the classification of antiarrhythmic agents. Int. J. Cardiol. 21: 211-217, 1988.
7. Manoach M., Varon D., Erez M. The role of catecholamines on intracellular coupling, myocardial cell synchronization and self ventricular defibrillation. Mol. Cell. Biochem. 147: 181-185, 1995.
8. Manoach M., Erez M., Varon D. Properties required for self ventricular defibrillation: Influence of age and drugs. Cardiol. Elderly. 1: 337-344, 1993.
9. Manoach M., Beker B., Erez M., Varon D., Netz H. Spontaneous termination of electrically induced ventricular fibrillation. In: Macfarlane P.W. ed. Progress in Electrophysiology. London: Pitman Medical Publications Ltd, pp. 361-365, 1979.
10. Erez M., Varon D. Dibenzazepines and phenothiazines – A winding path to defibrillatory antiarrhythmic agents. Exp. Clin. Cardiol. 2; 59-63, 1997.
11. Kaverina N.V., Skoldinov A.P. New cardiovascular drugs among